MANKIND

Mankind Pharma Share Price

 

 

Invest in Mankind Pharma with 3.54X leverage

Invest with MTF

Performance

  • Low
  • ₹2,160
  • High
  • ₹2,190
  • 52 Week Low
  • ₹2,115
  • 52 Week High
  • ₹3,055
  • Open Price₹2,172
  • Previous Close₹2,186
  • Volume101,058

Investment Returns

  • Over 1 Month -3.66%
  • Over 3 Month -15.52%
  • Over 6 Month -7.37%
  • Over 1 Year -15.75%

Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!

Invest Now

Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 51.4
  • PEG Ratio
  • -3
  • Market Cap Cr
  • 90,078
  • P/B Ratio
  • Average True Range
  • 40.84
  • EPS
  • 42.36
  • Dividend Yield
  • 0
  • MACD Signal
  • -45.59
  • RSI
  • 29.33
  • MFI
  • 36.62

Mankind Pharma Financials

Mankind Pharma Technicals

EMA & SMA

Current Price
₹2,182.10
-3.4 (-0.16%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹2,247.17
  • 50 Day
  • ₹2,329.32
  • 100 Day
  • ₹2,393.08
  • 200 Day
  • ₹2,422.91

Resistance and Support

2185.93 Pivot Speed
  • R3 2,248.87
  • R2 2,228.03
  • R1 2,206.77
  • S1 2,164.67
  • S2 2,143.83
  • S3 2,122.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mankind Pharma Ltd. is one of India’s largest pharmaceutical companies, providing a wide range of affordable medicines in areas like antibiotics, cardiovascular, gastrointestinal, and dermatology. It also manufactures over-the-counter (OTC) products, catering to domestic and global markets.

Mankind Pharma Ltd has an operating revenue of Rs. 13,576.88 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 13% is good. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 28% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 45 which is a POOR score indicating inconsistency in earnings, a RS Rating of 45 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 127 indicates it belongs to a poor industry group of Medical-Products and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mankind Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-07-31 Quarterly Results & Interim Dividend
2025-05-21 Audited Results
2025-01-23 Quarterly Results
2024-11-05 Quarterly Results
Date Purpose Remarks
2025-08-08 INTERIM Rs.1.00 per share(100%)Interim Dividend
View Mankind Pharma Dividend History Arrow

Mankind Pharma F&O

Mankind Pharma Shareholding Pattern

72.67%
7.78%
1.77%
12.83%
0%
1.36%
3.59%

Mankind Pharma FAQs

Mankind Pharma share price is ₹2,182 As on 09 December, 2025 | 12:03

The Market Cap of Mankind Pharma is ₹90078.2 Cr As on 09 December, 2025 | 12:03

The P/E ratio of Mankind Pharma is 51.4 As on 09 December, 2025 | 12:03

The PB ratio of Mankind Pharma is 6.3 As on 09 December, 2025 | 12:03

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23